Cargando…

Clinical Significance of Mean and Pulse Pressure in Patients With Heart Failure With Preserved Ejection Fraction

It remains debated whether pulse pressure is associated with left ventricular traits and adverse outcomes over and beyond mean arterial pressure (MAP) in patients with heart failure (HF) with preserved ejection fraction. We investigated these associations in 3428 patients with HF with preserved ejec...

Descripción completa

Detalles Bibliográficos
Autores principales: Wei, Fang-Fei, Wu, Yuzhong, Xue, Ruicong, Liu, Xiao, He, Xin, Dong, Bin, Zhen, Zhe, Chen, Xuwei, Liang, Weihao, Zhao, Jingjing, He, Jiangui, Dong, Yugang, Staessen, Jan A., Liu, Chen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8654124/
https://www.ncbi.nlm.nih.gov/pubmed/34739763
http://dx.doi.org/10.1161/HYPERTENSIONAHA.121.17782
_version_ 1784611800115838976
author Wei, Fang-Fei
Wu, Yuzhong
Xue, Ruicong
Liu, Xiao
He, Xin
Dong, Bin
Zhen, Zhe
Chen, Xuwei
Liang, Weihao
Zhao, Jingjing
He, Jiangui
Dong, Yugang
Staessen, Jan A.
Liu, Chen
author_facet Wei, Fang-Fei
Wu, Yuzhong
Xue, Ruicong
Liu, Xiao
He, Xin
Dong, Bin
Zhen, Zhe
Chen, Xuwei
Liang, Weihao
Zhao, Jingjing
He, Jiangui
Dong, Yugang
Staessen, Jan A.
Liu, Chen
author_sort Wei, Fang-Fei
collection PubMed
description It remains debated whether pulse pressure is associated with left ventricular traits and adverse outcomes over and beyond mean arterial pressure (MAP) in patients with heart failure (HF) with preserved ejection fraction. We investigated these associations in 3428 patients with HF with preserved ejection fraction (51.5% women; mean age, 68.6 years) enrolled in the TOPCAT trial (Treatment of Preserved Cardiac Function Heart Failure With an Aldosterone Antagonist). We computed association sizes and hazards ratios with 1-SD increase in MAP and pulse pressure. In multivariable-adjusted analyses, association sizes (P≤0.039) for MAP were 0.016 cm and 0.014 cm for septal and posterior wall thickness, −0.15 for E/A ratio, −0.66 for E/e′, and −0.64% for ejection fraction, independent of pulse pressure. With adjustment additionally applied for MAP, E/A ratio and longitudinal strain increased with higher pulse pressure with association sizes amounting to 0.067 (P=0.026) and 0.40% (P=0.023). In multivariable-adjusted analyses of both placebo and spironolactone groups, lower MAP and higher pulse pressure predicted the primary composite end point (P≤0.028) and hospitalized HF (P≤0.002), whereas MAP was also significantly associated with total mortality (P≤0.007). Sensitivity analyses stratified by sex, median age, and region generated confirmatory results with exception for the association of adverse outcomes with pulse pressure in patients with age ≥69 years. In conclusion, the clinical application of MAP and pulse pressure may refine risk estimates in patients with HF with preserved ejection fraction. This finding may help further investigation for the development of HF with preserved ejection fraction preventive strategies targeting pulsatility and blood pressure control.
format Online
Article
Text
id pubmed-8654124
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Lippincott Williams & Wilkins
record_format MEDLINE/PubMed
spelling pubmed-86541242021-12-09 Clinical Significance of Mean and Pulse Pressure in Patients With Heart Failure With Preserved Ejection Fraction Wei, Fang-Fei Wu, Yuzhong Xue, Ruicong Liu, Xiao He, Xin Dong, Bin Zhen, Zhe Chen, Xuwei Liang, Weihao Zhao, Jingjing He, Jiangui Dong, Yugang Staessen, Jan A. Liu, Chen Hypertension Original Articles It remains debated whether pulse pressure is associated with left ventricular traits and adverse outcomes over and beyond mean arterial pressure (MAP) in patients with heart failure (HF) with preserved ejection fraction. We investigated these associations in 3428 patients with HF with preserved ejection fraction (51.5% women; mean age, 68.6 years) enrolled in the TOPCAT trial (Treatment of Preserved Cardiac Function Heart Failure With an Aldosterone Antagonist). We computed association sizes and hazards ratios with 1-SD increase in MAP and pulse pressure. In multivariable-adjusted analyses, association sizes (P≤0.039) for MAP were 0.016 cm and 0.014 cm for septal and posterior wall thickness, −0.15 for E/A ratio, −0.66 for E/e′, and −0.64% for ejection fraction, independent of pulse pressure. With adjustment additionally applied for MAP, E/A ratio and longitudinal strain increased with higher pulse pressure with association sizes amounting to 0.067 (P=0.026) and 0.40% (P=0.023). In multivariable-adjusted analyses of both placebo and spironolactone groups, lower MAP and higher pulse pressure predicted the primary composite end point (P≤0.028) and hospitalized HF (P≤0.002), whereas MAP was also significantly associated with total mortality (P≤0.007). Sensitivity analyses stratified by sex, median age, and region generated confirmatory results with exception for the association of adverse outcomes with pulse pressure in patients with age ≥69 years. In conclusion, the clinical application of MAP and pulse pressure may refine risk estimates in patients with HF with preserved ejection fraction. This finding may help further investigation for the development of HF with preserved ejection fraction preventive strategies targeting pulsatility and blood pressure control. Lippincott Williams & Wilkins 2021-11-05 2022-01 /pmc/articles/PMC8654124/ /pubmed/34739763 http://dx.doi.org/10.1161/HYPERTENSIONAHA.121.17782 Text en © 2021 The Authors. https://creativecommons.org/licenses/by-nc-nd/4.0/Hypertension is published on behalf of the American Heart Association, Inc., by Wolters Kluwer Health, Inc. This is an open access article under the terms of the Creative Commons Attribution Non-Commercial-NoDerivs (https://creativecommons.org/licenses/by-nc-nd/4.0/) License, which permits use, distribution, and reproduction in any medium, provided that the original work is properly cited, the use is noncommercial, and no modifications or adaptations are made. This article is made available via the PMC Open Access Subset for unrestricted re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the COVID-19 pandemic or until permissions are revoked in writing. Upon expiration of these permissions, PMC is granted a perpetual license to make this article available via PMC and Europe PMC, consistent with existing copyright protections.
spellingShingle Original Articles
Wei, Fang-Fei
Wu, Yuzhong
Xue, Ruicong
Liu, Xiao
He, Xin
Dong, Bin
Zhen, Zhe
Chen, Xuwei
Liang, Weihao
Zhao, Jingjing
He, Jiangui
Dong, Yugang
Staessen, Jan A.
Liu, Chen
Clinical Significance of Mean and Pulse Pressure in Patients With Heart Failure With Preserved Ejection Fraction
title Clinical Significance of Mean and Pulse Pressure in Patients With Heart Failure With Preserved Ejection Fraction
title_full Clinical Significance of Mean and Pulse Pressure in Patients With Heart Failure With Preserved Ejection Fraction
title_fullStr Clinical Significance of Mean and Pulse Pressure in Patients With Heart Failure With Preserved Ejection Fraction
title_full_unstemmed Clinical Significance of Mean and Pulse Pressure in Patients With Heart Failure With Preserved Ejection Fraction
title_short Clinical Significance of Mean and Pulse Pressure in Patients With Heart Failure With Preserved Ejection Fraction
title_sort clinical significance of mean and pulse pressure in patients with heart failure with preserved ejection fraction
topic Original Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8654124/
https://www.ncbi.nlm.nih.gov/pubmed/34739763
http://dx.doi.org/10.1161/HYPERTENSIONAHA.121.17782
work_keys_str_mv AT weifangfei clinicalsignificanceofmeanandpulsepressureinpatientswithheartfailurewithpreservedejectionfraction
AT wuyuzhong clinicalsignificanceofmeanandpulsepressureinpatientswithheartfailurewithpreservedejectionfraction
AT xueruicong clinicalsignificanceofmeanandpulsepressureinpatientswithheartfailurewithpreservedejectionfraction
AT liuxiao clinicalsignificanceofmeanandpulsepressureinpatientswithheartfailurewithpreservedejectionfraction
AT hexin clinicalsignificanceofmeanandpulsepressureinpatientswithheartfailurewithpreservedejectionfraction
AT dongbin clinicalsignificanceofmeanandpulsepressureinpatientswithheartfailurewithpreservedejectionfraction
AT zhenzhe clinicalsignificanceofmeanandpulsepressureinpatientswithheartfailurewithpreservedejectionfraction
AT chenxuwei clinicalsignificanceofmeanandpulsepressureinpatientswithheartfailurewithpreservedejectionfraction
AT liangweihao clinicalsignificanceofmeanandpulsepressureinpatientswithheartfailurewithpreservedejectionfraction
AT zhaojingjing clinicalsignificanceofmeanandpulsepressureinpatientswithheartfailurewithpreservedejectionfraction
AT hejiangui clinicalsignificanceofmeanandpulsepressureinpatientswithheartfailurewithpreservedejectionfraction
AT dongyugang clinicalsignificanceofmeanandpulsepressureinpatientswithheartfailurewithpreservedejectionfraction
AT staessenjana clinicalsignificanceofmeanandpulsepressureinpatientswithheartfailurewithpreservedejectionfraction
AT liuchen clinicalsignificanceofmeanandpulsepressureinpatientswithheartfailurewithpreservedejectionfraction